Calcium channel blockers and beta-blockers in relation to Parkinson's disease.
We investigated the risk of Parkinson's disease (PD) associated with calcium channel blockers (CCBs) and beta-blockers in a population-based case-control study of 206 men and women between ages 35 and 89 with a new diagnosis of idiopathic PD between 1992 and 2002, and 383 controls without PD or other neurodegenerative disorders who were frequency matched on age, sex, duration of GHC enrollment and clinic. The adjusted odds ratio associated with ever use was 0.85 (95% confidence interval [CI]: 0.43, 1.66) for CCBs, and 1.20 (95% CI: 0.71, 2.03) for beta-blockers. We observed no association with PD risk for either class of medication in terms of duration, dose, number of prescriptions or pattern of use. The weakness of these associations and the absence of additional influence of dose or duration of use argue against any causal interpretation.
Ton
Thanh G N
TG
Department of Epidemiology, University of Washington, Box 357236, Seattle, WA 98195-7326, USA. thanhton@u.washington.edu
Heckbert
Susan R
SR
Longstreth
W T
WT
Rossing
Mary Anne
MA
Kukull
Walter A
WA
Franklin
Gary M
GM
Swanson
Phillip D
PD
Smith-Weller
Terri
T
Checkoway
Harvey
H
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002121:Calcium Channel Blockers / Q000009:adverse effects*; D016022:Case-Control Studies; D018672:Community Health Planning; D016001:Confidence Intervals; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D010300:Parkinson Disease / Q000453:epidemiology* / Q000209:etiology*; D012189:Retrospective Studies; D012306:Risk; D013997:Time Factors
D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers